DelveInsight’s, “Chronic Spontaneous Urticaria Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the Chronic Spontaneous Urticaria pipeline drug profiles, including Chronic Spontaneous Urticaria clinical trials and nonclinical stage products. It also covers the Chronic Spontaneous Urticaria therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Chronic Spontaneous Urticaria Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Chronic Spontaneous Urticaria Pipeline landscape @ Chronic Spontaneous Urticaria Pipeline Outlook Report
Chronic Spontaneous Urticaria Overview
Urticaria (also called hives, wheals, or nettle rash) is characterized by pruritic, erythematous, and edematous wheals. Chronic Spontaneous Urticaria (CSU) is defined as hives that are present for at least or greater than 6 weeks and for the most days of the week. Chronic spontaneous urticaria is characterized by the presence of weals and angioedema.
Recent Developmental Activities in the Chronic Spontaneous Urticaria Treatment Landscape
For further information, refer to the detailed Chronic Spontaneous Urticaria Drugs Launch, Chronic Spontaneous Urticaria Developmental Activities, and Chronic Spontaneous Urticaria News, click here for Chronic Spontaneous Urticaria Ongoing Clinical Trial Analysis
Chronic Spontaneous Urticaria Emerging Drugs Profile
Dupilumab: Sanofi
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. Dupixent is approved for use in certain patients with atopic dermatitis, asthma, CRSwNP or EoE in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including chronic spontaneous urticaria, which is in the preregistration developmental stage.
Tezepelumab: Amgen
Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP). The drug is in Preregistration for Asthma treatment; in Phase III for rhinosinusitis; in Phase II clinical studies for the treatment of chronic urticarial and chronic obstructive pulmonary disease. Tezepelumab is being developed in collaboration with AstraZeneca.
Barzolvolimab: Celldex Therapeutics
Barzolvolimab (CDX-0159) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival, and activity of mast cells. In certain inflammatory diseases, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is being evaluated in the Phase II development stage for the treatment of chronic spontaneous urticaria.
Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Chronic Spontaneous Urticaria. The companies which have their Chronic Spontaneous Urticaria drug candidates in the most advanced stage, i.e. preregistration, Sanofi.
Find out more about the Chronic Spontaneous Urticaria Diagnosis and Treatment of patients @ Chronic Spontaneous Urticaria Ongoing Clinical Trials Analysis
Scope of the Chronic Spontaneous Urticaria Pipeline Report
Discover more about the list of FDA-approved drugs for Chronic Spontaneous Urticaria @ Chronic Spontaneous Urticaria Treatment Landscape
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/